Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL28B in the era of direct-acting antivirals for hepatitis C.

Journal of clinical gastroenterology - 1 Mar 2013

Muir Andrew J

Abstract excerpt

The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-α and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-α and ribavirin, and boceprevir and telaprevir attenuate the associa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepacivirus
Share to Hepatitis C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferons

Share to Interleukins

Share to Oligopeptides

Share to Proline

Share to Treatment Outcome

Source

Identifiers

PMID: 23328301
DOI: 10.1097/MCG.0b013e3182680221

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-23328301-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL28B in the era of direct-acting antivirals for hepatitis C.PMID 23328301Read ↗

Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?Semantic proximity Read ↗

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Semantic proximity Read ↗

Role of IL28B for chronic hepatitis C treatment toward personalized medicine.Semantic proximity Read ↗

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.Semantic proximity Read ↗

Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?Semantic proximity Read ↗

Effect of IL28B genotype on hepatitis B and C virus infection.Semantic proximity Read ↗

IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?Semantic proximity Read ↗

Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance.Semantic proximity Read ↗

Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Semantic proximity Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

IL28B single nucleotide polymorphisms in the treatment of hepatitis C.Semantic proximity Read ↗

IL28B polymorphism and the control of hepatitis C virus infection: ready for clinical use?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.